Hyperoxemia in the Intensive Care Unit(ICU) (ICU)

April 18, 2026 updated by: Gökhan Günbay, Trakya University

Investigation of the Outcomes of Hyperoxemia in Patients Treated in the Intensive Care Unit

In our study, to research the prevalence of hyperoxemia in adult patients treated in the intensive care unit (ICU) and its relationship with clinical outcomes. This single-center, observational study included 260 consecutive patients aged 18-85 years who received oxygen therapy in the ICU for respiratory failure. Hyperoxia was defined as SpO₂>96% and PaO₂>100 mmHg in the first 24 hours. Patients were divided into normoxic and hyperoxic groups, and demographic characteristics, comorbidities, ICU admission scores, mechanical ventilation requirements, ICU and hospital length of stay, and in-hospital mortality were compared.The mean age of the patients was 69.9±15.4 years, and 55.8% were male. According to SpO₂-PaO₂ criteria, hyperoxia was detected in 59.6% (n=155) of patients and normoxia in 40.4% (n=105). The groups were similar in terms of age, gender, BMI, and APACHE II score. The SOFA score and admission GCS were lower in the hyperoxic group, and the duration of mechanical ventilation, ICU, and hospital stays were significantly longer (p<0.01 for all). In-hospital mortality was significantly higher in the hyperoxic group (82.5% vs. 50.4%; p<0.001).

In our study, hyperoxia developed in approximately two-thirds of the patients in the ICU, and hyperoxia was associated with increased mortality and length of stay. These results highlight the importance of avoiding hyperoxia when titrating oxygen therapy in critically ill patients.

Study Overview

Detailed Description

In this study; It was aimed to examine the effects of non-invasive and invasive oxygen therapy on hyperoxemia in patients treated in the intensive care unit of Trakya University Hospital.Patients aged 18-85, who received non-invasive or invasive oxygen therapy as indicated due to respiratory failure and who were detected to have hyperoxia in the first 24 hours of treatment, were included in the study. SpO2 > 96% and PaO2 > 100 were considered hyperoxia. HFNO, CPAP and simple face mask oxygen therapy methods were used as noninvasive respiratory support methods. Patients who stayed in the intensive care unit for less than 24 hours, patients with suspected brain death, and patients with suspected pregnancy were excluded from the study. The patients' respiratory failure was treated as indicated. All patients were evaluated according to their age, gender, whether they were intubated during the ICU stay, mechanical ventilation duration if intubated, on which day they were extubated, duration of ICU stay, highest PaO2 values in the first 24 hours of ICU stay, hourly oxygen saturation levels and mortality rates. recorded from the patient file. The findings were compared with each other and it was aimed to determine which treatment methods caused more hyperoxia. In the study, it was found that 40.4% of all patients were normoxic, 59.6% were hyperoxic, 42.5% of those receiving oxygen mask therapy, 60% of those receiving HFNO therapy, 63.4% of those receiving CPAP therapy and It was found that 63.2% of those receiving IMV treatment were in the hyperoxic group. When the transition from respiratory therapy to IMV is examined; While the rate of switching from oxygen mask therapy to IMV was found to be similar in both groups, the rate of switching from HFNO and CPAP treatments to IMV was found to be statistically significantly higher in the Hyperoxia group than in the Normoxative group. In conclusion; The fact that hyperoxemia has both positive and negative aspects both in the literature and in our study necessitates the need for studies on this subject to be carried out in isolation and with a higher number of cases. Such studies will enable better evaluation of hyperoxemia in the future.

Study Type

Observational

Enrollment (Actual)

260

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Merkez
      • Edirne, Merkez, Turkey (Türkiye), 22100
        • Trakya Universitesi Tip Fakultesi

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Sampling Method

Probability Sample

Study Population

The study included 260 patients aged 18-85 years who received non-invasive or invasive oxygen therapy for respiratory failure as indicated in the Surgical, Reanimation and Postoperative intensive care units of Trakya University Faculty of Medicine Hospital and who were found to have hyperoxia within the first 24 hours of treatment.

Description

Inclusion Criteria:

  • Patients between the ages of 18-85
  • Patients in the intensive care unit receiving non-invasive or invasive oxygen therapy due to respiratory failure
  • Patients who develop hyperoxia within the first 24 hours of treatment

Exclusion Criteria:

  • Patients who stayed in the intensive care unit for less than 24 hours
  • Patients suspected of brain death
  • Patients suspected of being pregnant

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
hyperoxemia group
SpO2 > %96 , PaO2>100 mmHg
normoxemia group
SpO2:% 92-96 , PaO2: 60-100 mmHg

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
In which treatment methods is more hyperoxia observed
Time Frame: through study completion, an average of 2 year
The incidence of hyperoxemia was compared in oxygen support therapies such as simple face masks, HFNO, and CPAP.
through study completion, an average of 2 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Chair: MEHMET TURAN İNAL, Trakya University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 1, 2021

Primary Completion (Actual)

December 31, 2023

Study Completion (Actual)

December 31, 2023

Study Registration Dates

First Submitted

April 13, 2026

First Submitted That Met QC Criteria

April 18, 2026

First Posted (Actual)

April 24, 2026

Study Record Updates

Last Update Posted (Actual)

April 24, 2026

Last Update Submitted That Met QC Criteria

April 18, 2026

Last Verified

April 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • TÜTF-BAEK 2021/174

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Mortality

Subscribe